These include CD-19 targeting therapies, such as tisagenlecleucel (Kymriah), axicabtagene ciloleucel (Yescarta), brexucabtagene autoleucel (Tecartus), and lisocabtagene maraleucel (Breyanzi), which have demonstrated exceptional efficacy in treating relapsed or refractory B-cell lymphomas and acute lymphoblastic leukemia (ALL) (4–7). This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.